Investment

SENISCA seeks funding for senescence reversal

University of Exeter spinout raising seed investment as it targets aging aesthetics and age-related disease with ground-breaking rejuvenation technology. Deep in the labs at the...

SyndicateRoom co-founder joins First Longevity

Tom Britton joins Advisory Panel as plans for Longevity equity funding platform take another step forward. Longevity.Technology: Just last month we announced the formation of...

Longevity investment: Apollo aims for the moon

Co-founder of Longevity-focused investment firm shows you can target aging AND appeal to biotech investors. Founded in 2016, Berlin and Boston-based Apollo already boasts an...

Cosmetic therapeutic senolytics: aging isn’t just skin-deep

When is a cosmetic product also a therapy? When it's a patented senolytic that tackles aging at a cellular level. OneSkin began life validating how...

Unlocking the Longevity potential of our oceans

Biologist focuses on the coast of Oman to discover how extreme environments and oceanic life could provide sources for Longevity. With issues like climate change, overfishing...

G3 and Juvenescence partner on deep learning venture

G3 Therapeutics and Juvenescence announce the formation of Juvenomics to apply deep molecular profiling and deep learning to tackle aging. Juvenomics, a joint venture between...

New initiative offers boost for health innovators

A new health tech accelerator aims to support small businesses and enterprises in the fight against the aging process. The UK's Industrial Strategy Challenge Fund has...

Fountain Therapeutics inks new $6m finance deal

New funding for AI and computer vision Longevity drug discovery start-up. The saying goes: “Some people drink from the fountain of knowledge. Others just gargle.”...

Jim Mellon donates £1 million to Oriel for aging research

Oxford University's Longevity science given a £1 million boost by donation. Oriel College, Oxford, is a focal point for the efforts to improve future health...

The next generation of Longevity investment

What’s driving Kingsley Advani to get involved in the fight against aging? What do Juvenescence, Oisín Biotechnologies, Volumetric and GEn1E Lifesciences have in common? Yes,...

Applying theoretical physics to Longevity drug discovery

Peter Fedichev's Gero raising $10 million for anti-aging drug discovery and clinical trials. The use of AI in Longevity drug discovery is nothing new, Insilico...

Regenerative medicine start-up raises $28.5 million

A Baltimore based biotech start-up, LifeSprout, has closed a $28.5million round of series A financing as it prepares for the launch of clinical trials...

Longevity2020: Day 4 recap

Yesterday at Longevity2020 was all about how the Longevity sector is growing an investment category. Speakers included top investors, as well as the entrepreneurs behind...

Oisín on aging as a disease and raising $5m seed

Co-founder Gary Hudson talks cell senescence, trials, spin-outs and the dilemma of treating age as a disease. Every entrepreneur in Longevity has a different story...

Juvenescence CEO on near-term Longevity breakthroughs

We talk pipeline, trials, raising capital and public company challenges with Juvenescence's Dr Greg Bailey. Longevity.Technology: Longevity is growing as a distinct investment category and Thursday’s...

Talking Longevity investment and risk with R42 Group

Longevity investment is growing and we're seeing a mixture of funds and investment platforms. We chat with the founder of R42 Group. R42 Group actively invents...

The Longevity landscape and investment potential

Hype or hyper-exciting? Kate Batz of Longevity.Capital shares her views on the Longevity landscape and its investment potential: pragmatic optimism, but full of opportunity. In the...

Cerevance raising $60m for brain disease drug discovery

Company awaits Phase 2 trial readout for new Parkinson’s drug as part of its mission to combat brain disease. In the world of Longevity start-ups,...

VR for brain training and tracking cognitive health

Virtuleap currently fundraising to build headcount and capitalise on cognitive illness detection algorithms. Ever since the US Federal Trade Commission fined Lumosity $2 million for...

Start-ups – are you solving a meaningful problem?

Forward Partners’ Luke Smith shares his views on early stage investment. With the inaugural Biohacking Congress arriving in London tomorrow, we had just enough time...

Latest articles

Evidence for tenth hallmark of aging increases with new paper

Is ten the new nine? Additional research adds weight to the argument that extracellular matrix stiffening should be considered the tenth hallmark of aging. Since...

Help us help you: Longevity biotech survey

A new survey on translational processes and hurdles to clinical trials in Longevity biotech. We're working with two MDs: Oliver Zolman and Jian Fransen, on...

First Longevity announces first investors for current round

Some news of our own: European VC fund and a Longevity innovator participate in the First Longevity funding round. Last week we announced that Tom...

GDF15 protects from age‐related metabolic phenotypes

A recent study shows an important role for GDF15 in preventing aging-induced metabolic phenotypes by modulating systemic inflammatory responses in humans and mice. Dysfunction of...